More Phase III success for Lucentis in DMO, but spectre of Avastin comparison awaits
28 March 2011
Pial Ganguli
Please Login to read the full article.
28 March 2011
Pial Ganguli
Please Login to read the full article.
RELATED CONTENT
NEWS
- Genentech eye implant to improve delivery of Lucentis may improve sales, too
- IVAN adds to pressure on Lucentis with £85m UK savings claim
- CATT 2-year results add fuel to Avastin/Lucentis debate, with implications for Eylea
- Bayer, Regeneron begin PhIII trials for Eylea in China for wet AMD
COMMENT
Other Informa Comment
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
